Immunocore to present at upcoming investor conferences
08 nov. 2024 07h00 HE
|
Immunocore Holdings plc
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology...
Immunocore reports third quarter financial results and provides a business update
06 nov. 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in...
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer
14 sept. 2024 03h00 HE
|
Immunocore Holdings plc
Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer Brenetafusp is clinically active as monotherapy and in combination with...
Immunocore to present at the 2024 Cantor Global Healthcare Conference
12 sept. 2024 16h05 HE
|
Immunocore Holdings plc
Immunocore to present at the 2024 Cantor Global Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 12 September 2024) Immunocore Holdings plc (Nasdaq:...
Immunocore announces transition of Chief Financial Officer
29 août 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore announces transition of Chief Financial Officer (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 29 August 2024) Immunocore Holdings plc (Nasdaq: IMCR)...
Immunocore reports second quarter financial results and provides a business update
08 août 2024 07h00 HE
|
Immunocore Holdings plc
KIMMTRAK® (tebentafusp-tebn) net revenues of $75.3 million in 2Q 2024 driven by US growth Registrational Phase 3 TEBE-AM trial with KIMMTRAK in previously treated cutaneous melanoma ongoing,...
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
01 août 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 01 August 2024) Immunocore...
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma
18 juin 2024 07h00 HE
|
Immunocore Holdings plc
Immunocore announces randomization of first patient in the global, registrational Phase 3 clinical trial testing brenetafusp for the treatment of first-line advanced or metastatic cutaneous melanoma ...
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
01 juin 2024 08h00 HE
|
Immunocore Holdings plc
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response Data were...
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
31 mai 2024 16h05 HE
|
Immunocore Holdings plc
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024 Monotherapy...